Our Team - Carlsmed
Transforming Spine Surgery Through Personalized Solutions
Our mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. The Carlsmed aprevo® personalized surgery platform is designed to improve the standard of care for spine surgery one patient at a time.
Our Core Values
We are committed to three guiding principles:
- PATIENT-OBSESSED.
- DO WHAT IS RIGHT.
- ACHIEVE TOGETHER.
Executive Leadership Team
Mike Cordonnier
Chief Executive Officer
Leo Greenstein
Chief Financial Officer
Jennifer Kamocsay
Chief Legal Officer
Scott Durall
Chief Commercial Officer
Sharon Schulzki
Chief Clinical & Market Access Officer
Shariq Hussain
Chief Technology Officer
Niall Casey
Chief Intellectual Property Officer
Jeff Bertolini
Senior Vice President, Operational Excellence
Jodi Allen
Senior Vice President, People and Culture
Julie Lamothe
Senior Vice President, Quality & Regulatory Affairs
Samantha Beszeditz
Executive Assistant to Mike Cordonnier, CEO
Board of Directors
Mike Cordonnier
Mike Cordonnier is the Co-Founder, President and Chief Executive Officer at Carlsmed, and serves as the Chair of the Board of Directors.
Kevin Sidow
Kevin Sidow is the Lead Independent Director and serves as Chair of the Compensation Committee, as well as a member of the Audit and Nominating & Corporate Governance Committees on the Carlsmed Board of Directors.
Kevin O’Boyle
Kevin O’Boyle serves as Chair of the Audit Committee and is a member of the Compensation Committee on the Carlsmed Board of Directors.
Jonathan Root, M.D., M.B.A.
Dr. Jonathan Root serves as Chair of the Nominating and Corporate Governance Committee on the Carlsmed Board of Directors.
Robert Mittendorf, M.D., M.B.A.
Dr. Robert Mittendorf serves as a member of the Compensation Committee and the Nominating and Corporate Governance Committee on the Carlsmed Board of Directors.
Phil Young, M.B.A.
Phil Young serves as a member of the Audit Committee on the Carlsmed Board of Directors.
Niall Casey, J.D.
Niall Casey is the Co-Founder and Chief Intellectual Property Officer at Carlsmed and serves on the Board of Directors.
Paving the Way for the Future of Spinal Fusion Surgery
First company to receive FDA Breakthrough Device Designation for Intervertebral Spine Fusion Technology
2020
July
- aprevo® Lumbar receives FDA Breakthrough Device Designation
December
- FDA 510(k) clearance granted for aprevo® Lumbar
2021
February
- First aprevo® ALIF procedure performed in a patient
June
- First aprevo® LLIF procedure performed in a patient
August
- First aprevo® TLIF-O procedure performed in a patient
October
- aprevo® Lumbar receives CMS NTAP reimbursement and TPT payment approval
2022
August
- First aprevo® TLIF-C procedure performed in a patient
October
- Enrollment begins for the COMPASS™ personalized spine surgery study
2023
January
- First aprevo® ALIF-X procedure performed in a patient
September
- Carlsmed receives second FDA Breakthrough Device Designation for cervical technology
2024
August
- First aprevo® TLIF-CA procedure performed in a patient
November
- Launch of Carlsmed’s cutting-edge digital production line
December
- FDA 510(k) clearance granted for aprevo® Cervical
2025
June
- First aprevo® Lumbar Angled Solutions procedure performed in a patient
July
- First aprevo® ACDF procedure performed in a patient
- First aprevo® ACDF-X procedure performed in a patient
- Carlsmed completes Initial Public Offering and begins trading on Nasdaq
August
- CMS awards NTAP reimbursement for aprevo® Cervical procedures
November
- Launch of the myaprevo® Ecosystem
December
- Launch of the aprevo® Technology Platform for Cervical Fusion
- aprevo® Lumbar 2-year data published in Global Spine Journal
2026
February
- First aprevo® bi-lateral posterior procedure performed in a patient
aprevo® is FDA-cleared in the U.S. for lumbar and cervical spinal fusion indications only.